Close Menu

Vertex

NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

Treatment So Far

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.

A CRISPR Go

US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.

Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.

In Science this week: pair of genomics studies on ancient animals, and more.

The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.

NEW YORK (GenomeWeb) — Vertex Pharmaceuticals this week released data from two Phase III studies of a combination of its cystic fibrosis drugs lumacaftor and Kalydeco (ivacaftor), showing that the studies have met their primary endpoints of statistically significant improvement in lung function a

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.